SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed prostate cancer not amenable to curative treatment with surgery or radiotherapy
• Progressive disease defined by 1 of the following criteria:
• * New bone scan lesions
• * New or progressive radiologic lesions
• * Sequential increases in PSA on at least 2 successive measurements no less than 2 weeks apart of at least 50% above nadir on prior therapy provided absolute value at time of enrollment is at least 5 ng/mL
• Progressive disease, as defined above, despite adequate hormonal therapy defined by all of the following:
• * Continued treatment with an LHRH agonist or prior orchiectomy
• * Sequential or concurrent treatment with an antiandrogen (e.g., flutamide, nilutamide, or bicalutamide)
• * Trial of antiandrogen withdrawal at least 4 weeks prior to study
• CNS metastasis allowed if:
• * Previously treated
• * Neurologically stable
• * Oral or intravenous steroids or anticonvulsants not required
• * Brain scan (CT or MRI) within the past 2 weeks shows no active or residual disease
• * Negative brain scan required if neurologic signs or symptoms suggestive of CNS metastasis
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• WHO 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Platelet count at least 75,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• Transaminases no greater than 2.5 times upper limit of normal
• Renal:
• Creatinine no greater than 2.0 mg/dL OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No uncompensated coronary artery disease
• No history of myocardial infarction or severe unstable angina within the past 6 months
• No severe peripheral vascular disease associated with diabetes mellitus
• No deep venous or arterial thrombosis within the past 3 months
• Pulmonary:
• No pulmonary embolism within the past 3 months
• Other:
• Not pregnant
• Fertile patients must use effective contraception
• No significant uncontrolled underlying medical or psychiatric illness
• No serious active infection
• No other prior or concurrent malignancy except nonmelanoma skin cancer unless completed therapy and considered to be at less than 30% risk of relapse
• No history of severe allergic or anaphylactic reactions to paclitaxel or docetaxel
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior systemic chemotherapy
• No other concurrent chemotherapy
• No other concurrent investigational antineoplastic drugs
• Endocrine therapy:
• See Disease Characteristics
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery:
• See Disease Characteristics
• At least 4 weeks since prior major surgery